Renal function and mortality in patients with atrial fibrillation

被引:6
作者
Liampas, Evangelos [1 ]
Kartas, Anastasios [1 ]
Samaras, Athanasios [1 ]
Papazoglou, Andreas S. [1 ]
Moysidis, Dimitrios, V [1 ]
Vrana, Eleni [1 ]
Botis, Michail [1 ]
Papanastasiou, Anastasios [1 ]
Baroutidou, Amalia [1 ]
Vouloagkas, Ioannis [1 ]
Karagiannidis, Efstratios [1 ]
Akrivos, Evangelos [1 ]
Tsalikakis, Dimitrios [2 ]
Fyntanidou, Varvara [3 ]
Karvounis, Haralambos [1 ]
Tzikas, Apostolos [4 ]
Giannakoulas, George [1 ]
机构
[1] AHEPA Univ Hosp, Dept Cardiol 1, Thessaloniki, Greece
[2] AHEPA Univ Hosp, Sch Med, Lab Comp Med Informat & Biomed Imaging Technol, Thessaloniki, Greece
[3] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Fac Hlth Sci, Sch Med,Anesthesiol Dept, Thessaloniki, Greece
[4] Interbalkan European Med Ctr, Thessaloniki, Greece
关键词
all-cause mortality; atrial fibrillation; chronic kidney disease; estimated glomerular filtration rate; stages of chronic kidney disease; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CLINICAL-PRACTICE; ORAL ANTICOAGULANTS; RISK-FACTORS; HEMODIALYSIS; OUTCOMES; STROKE; DEATH; GUIDELINES;
D O I
10.2459/JCM.0000000000001308
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim The aim of this study is to examine the association of the presence of chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR) values with mortality in patients with atrial fibrillation. Methods This posthoc analysis of a randomized controlled trial consisted of hospitalized patients with atrial fibrillation who were followed up for a median of 2.7 years after discharge. Kaplan-Meier curves, multivariate Cox-regression and spline curves were utilized to assess the association of CKD, CKD stages 2-5 according to the KDOQI guidelines, and the continuum of eGFR values with the primary outcome of all-cause death, and the secondary outcome of cardiovascular mortality. Results Out of 1064 hospitalized patients with atrial fibrillation, 465 (43.7%) had comorbid CKD. The presence of CKD was associated with an increased risk for both all-cause and cardiovascular mortality following hospitalization [adjusted hazard ratio (aHR): 1.60; 95% confidence intervals (95% CIs): 1.25-2.05 and aHR: 1.74; 95% CI: 1.30-2.33, respectively]. The aHRs for all-cause mortality in CKD stages 2-5, as compared with CKD stage 1 were 2.18, 2.62, 4.20 and 3.38, respectively (all P < 0.05). In spline curve analyses, eGFR values lower than 50 ml/min/1.73 m(2) were independent predictors of higher all-cause and cardiovascular mortality. Conclusion In recently hospitalized patients with atrial fibrillation, the presence of CKD was independently associated with decreased survival, which was significant across CKD stages 2-5, as compared with CKD stage 1. Values of eGFR lower than 50 ml/min/1.73 m(2) were incrementally associated with worse prognosis.
引用
收藏
页码:430 / 438
页数:9
相关论文
共 50 条
[41]   Kidney function monitoring and trajectories in patients with atrial fibrillation [J].
Hawkins, Nathaniel M. ;
Wiebe, Natasha ;
Andrade, Jason G. ;
Sandhu, Roopinder K. ;
Ezekowitz, Justin A. ;
Kaul, Padma ;
Tonelli, Marcello ;
McAlister, Finlay A. .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2023, 27 (12) :981-989
[42]   Glomerular filtration rate: A prognostic marker in atrial fibrillation-A subanalysis of the AntiThrombotic Agents Atrial Fibrillation [J].
Proietti, Riccardo ;
Gonzini, Lucio ;
Pizzimenti, Giovanni ;
Ledda, Antonietta ;
Sanna, Pietro ;
AlTurki, Ahmed ;
Russo, Vincenzo ;
Lencioni, Mauro .
CLINICAL CARDIOLOGY, 2018, 41 (12) :1570-1577
[43]   FEATURES OF ANTICOAGULANT THERAPY OF ATRIAL FIBRILLATION IN COMBINATION WITH IMPAIRED RENAL FUNCTION [J].
Novikova, T. N. .
KARDIOLOGIYA, 2021, 61 (10) :81-88
[44]   Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction [J].
Potpara, Tatjana S. ;
Ferro, Charles J. ;
Lip, Gregory Y. H. .
NATURE REVIEWS NEPHROLOGY, 2018, 14 (05) :337-351
[45]   Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction [J].
Kobalava, Z. D. ;
Shavarov, A. A. ;
Vatsik-Gorodetskaya, M. V. .
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2021, 17 (01) :62-72
[46]   Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry [J].
Wang, Ying ;
Ma, Chang-Sheng ;
Du, Xin ;
He, Liu ;
Li, Jie ;
Wang, Guo-Hong ;
Wen, Dan ;
Dong, Jian-Zeng ;
Pan, Jian-Hong ;
Lip, Gregory Y. H. .
BMC CARDIOVASCULAR DISORDERS, 2019, 19 (01)
[47]   Renal Impairment and Ischemic Stroke Risk Assessment in Patients With Atrial Fibrillation The Loire Valley Atrial Fibrillation Project [J].
Banerjee, Amitava ;
Fauchier, Laurent ;
Vourc'h, Patrick ;
Andres, Christian R. ;
Taillandier, Sophie ;
Halimi, Jean Michel ;
Lip, Gregory Y. H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (20) :2079-2087
[48]   Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry [J].
Asuncion Esteve-Pastor, Maria ;
Miguel Rivera-Caravaca, Jose ;
Roldan-Rabadan, Inmaculada ;
Roldan, Vanessa ;
Muniz, Javier ;
Rana-Miguez, Paula ;
Ruiz-Ortiz, Martin ;
Cequier, Angel ;
Bertomeu-Martinez, Vicente ;
Badimon, Lina ;
Anguita, Manuel ;
Lip, Gregory Y. H. ;
Marin, Francisco .
THROMBOSIS AND HAEMOSTASIS, 2018, 118 (02) :279-287
[49]   Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure [J].
Cortese, Francesca ;
Scicchitano, Pietro ;
Gesualdo, Michele ;
Ricci, Gabriella ;
Carbonara, Santa ;
Franchini, Carlo ;
Schiavone, Brigida Immacolata Pia ;
Corbo, Filomena ;
Ciccone, Marco Matteo .
CURRENT MEDICINAL CHEMISTRY, 2017, 24 (34) :3813-3827
[50]   The relationship between serum indoxyl sulfate and the renal function after catheter ablation of atrial fibrillation in patients with mild renal dysfunction [J].
Koike, Hideki ;
Morita, Toshisuke ;
Tatebe, Junko ;
Watanabe, Ippei ;
Koike, Makiko ;
Yao, Shintaro ;
Shinohara, Masaya ;
Yuzawa, Hitomi ;
Suzuki, Takeya ;
Fujino, Tadashi ;
Ikeda, Takanori .
HEART AND VESSELS, 2019, 34 (04) :641-649